Ana Maria Arance Fernandez, MD, PhD, Hospital Clinic of Barcelona, Barcelona, Spain discusses the initial results from a Phase II trial, LEAP-004 (NCT03776136). This study investigated the use of lenvatinib plus pembrolizumab for advanced melanoma previously treated with a PD-1 or PD-L1 inhibitor. The data reported support lenvatinib plus pembrolizumab as a potential treatment option for this patient population. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

свернуть